XM无法为美国居民提供服务。

Guardant's blood-based cancer test moves closer to Medicare coverage with FDA approval



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 4-Guardant's blood-based cancer test moves closer to Medicare coverage with FDA approval</title></head><body>

Adds CEO comments in paragraphs 5, 7; updates shares

By Leroy Leo

July 29 (Reuters) -Guardant Health GH.O said its blood test to detect cancer that starts in the colon or rectum got an approval from the U.S. Food and Drug Administration, with the test moving closer toward gaining coverage under the country's Medicare insurance program.

The company's shares were up 3.4% at $34.13 on Monday.

The test is approved for adults aged 45 and older who are at average risk for colorectal cancer.

Colonoscopies are considered the gold standard test, but screening rates for the type of cancer remain low due to issues such as their perceived inconvenience.

"Many people for different reasons are not going through that procedure, and in the United States, we don't have a lot more capacity to screen a lot more people through colonoscopy either," Guardant CEO AmirAli Talasaz said.

Guardant's test, known as Shield, has been available in the U.S. since 2022 for use by laboratories, for a self-pay price of $895, but is not covered under Medicare.

Talasaz expects Shield to be commercially available in the near future, adding that the test would be immediately eligible under Medicare coverage for ages 65 and above as it meets criteria outlined by the agency that regulates the health plans.

Guardant did not provide the self-pay price of the FDA-approved version of Shield.

Blood-based tests are also more convenient than feces-based tests, such as Exact Sciences' EXAS.O Cologuard, for cancer screening.

According to the FDA's documents, a study showed Guardant's Shield test detected 83% of colorectal cancers. Exact Sciences' stool test Cologuard had a 92.3% sensitivity rate.

Colorectal cancer occurs in about 150,000 patients in the U.S. annually and is the second-leading cause of cancer fatalities in the country, according to the FDA.

"The focus now turns to commercialization for Shield which ... will be a long, costly slog in primary care," William Blair analyst Andrew Brackmann said.



Reporting by Sneha S K, Leroy Leo and Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta

</body></html>

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明